Table 1 Baseline characteristics
All (n = 34) | Dose 3 (n = 28) | |
Median age, years (range) | 58.5 (38.0, 75.0) | 58.0 (38.0, 70.0) |
Sex, n (%) | ||
Male | 32 (94.1) | 26 (92.9) |
Female | 2 (5.9) | 2 (7.1) |
ECOG performance status, n (%) | ||
0 | 15 (44.1) | 13 (46.4) |
1 | 19 (55.9) | 15 (53.6) |
Primary tumor location at diagnosis, n (%) | ||
Gastroesophageal junction | 9 (26.5) | 8 (28.6) |
Gastric | 25 (73.5) | 20 (71.4) |
Histology, n (%) | ||
Intestinal type | 14 (41.2) | 11 (39.3) |
Diffuse type | 5 (14.7) | 2 (7.1) |
Mixed | 7 (20.6) | 7 (25.0) |
Unknown | 8 (23.5) | 8 (28.6) |
Differentiation type, n (%) | ||
Low | 19 (55.9) | 16 (57.1) |
Intermediate | 11 (32.4) | 8 (28.6) |
Unknown | 4 (11.8) | 4 (14.3) |
Number of organs with metastases | ||
≤1 | 12 (35.3) | 10 (35.7) |
≥2 | 22 (64.7) | 18 (64.3) |
Microsatellite status, n (%) | ||
Microsatellite stable (MSS) | 30 (88.2) | 24 (85.7) |
Microsatellite instability (MSI)-high | 1 (2.9) | 1 (3.6) |
MSI-low | 1 (2.9) | 1 (3.6) |
Unknown | 2 (5.9) | 2 (7.1) |
Tumor mutational burden (TMB), n (%) | ||
TMB-high | 13 (38.2) | 11 (39.3) |
TMB-low | 19 (55.9) | 15 (53.6) |
Unknown | 2 (5.9) | 2 (7.1) |
PD-L1 combined positive score (CPS), n (%) | ||
< 1 | 17 (50.9) | 12 (42.9) |
≥ 1 | 12 (35.3) | 11 (39.3) |
< 5 | 22 (64.7) | 17 (60.7) |
≥ 5 | 7 (20.6) | 6 (21.4) |
< 10 | 24 (70.6) | 19 (67.9) |
≥ 10 | 5 (14.7) | 4 (14.3) |
Unknown | 5 (14.7) | 5 (17.9) |
